19:06 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting CHI3L1 could help treat lung metastases of melanoma. In mouse melanoma cells co-cultured with mouse CD8+ T cells, CHI3L1 knockout in the T cells increased cytotoxic T...
21:32 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between patients who received twice-daily 800 mg oral PQ912...
08:00 , Dec 5, 2011 |  BioCentury  |  Product Development

Change-up for BATTER-UP

A year after starting a biomarker study in rheumatoid arthritis, a broad-based consortium has been forced to retool its recruitment strategy. The Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis -Unresponsive Populations Consortium had hoped...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer Chitinase 3-like 1 cartilage glycoprotein-39 (CHI3L1; YKL40) Cell culture and mouse studies suggest inhibiting CHI3L1...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation ...
07:00 , Apr 24, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation ...